Clincosm LogoSign in Get a demo

Study on the Protective Effect of Gastrodin on Myocardial Injury in Patients Undergoing Cardiac Surgery

Sponsor
Wuhan Union Hospital, China (Other)
Overall Status
Recruiting
CT.gov ID
NCT06012968
Collaborator
(none)
10
Enrollment
1
Location
2
Anticipated Duration (Months)
5
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study intends to include hypertrophic cardiomyopathy patients over 18 years old who underwent cardiac surgery in our hospital. Patients were divided into medication group and control group according to the use of gastrodin during operation. The patients ' myocardial tissue samples were collected, the postoperative prognosis data were observed and recorded, and the data were analyzed. The degree of myocardial tissue cell damage and postoperative clinical outcomes were compared between the two groups.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    10 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Study on the Protective Effect of Gastrodin on Myocardial Injury in Patients Undergoing Cardiac Surgery
    Anticipated Study Start Date :
    Aug 1, 2023
    Anticipated Primary Completion Date :
    Oct 1, 2023
    Anticipated Study Completion Date :
    Oct 1, 2023

    Arms and Interventions

    Arm Intervention/Treatment
    GAS
    Control

    Outcome Measures

    Primary Outcome Measures

    1. Degree of myocardial cell injury [During postoperative hospitalization stay, an average of about two weeks]

      Postoperative myocardial injury marker serum concentration, postoperative cardiac function ultrasound index

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Patients with hypertrophic cardiomyopathy agedā‰„18 years, regardless of gender;

    • Patients undergoing elective hypertrophic cardiomyopathy outflow tract surgery;

    • Signed informed consent, good compliance.

    Exclusion Criteria:

    • suffering from more serious genetic diseases (such as immunodeficiency, thalassemia, etc.);

    • moderate to severe malnutrition, moderate to severe anemia;

    • persistent infection;

    • severe preoperative underlying diseases (such as severe liver and kidney dysfunction)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan Hubei China 430022

    Sponsors and Collaborators

    • Wuhan Union Hospital, China

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Wuhan Union Hospital, China
    ClinicalTrials.gov Identifier:
    NCT06012968
    Other Study ID Numbers:
    • mzk202301
    First Posted:
    Aug 28, 2023
    Last Update Posted:
    Aug 28, 2023
    Last Verified:
    Aug 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No

    Study Results

    No Results Posted as of Aug 28, 2023